These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36091934)

  • 1. Improving outcomes for high-risk DLBCL: a pilot study looking at the role of fractionated cyclophosphamide with RCHOP chemo-immunotherapy (SCUBA-1 trial).
    Singh C; Malhotra P; Jandial A; Jain A; Lad D; Khadwal A; Bal A; Das A; Mittal BR; Prakash G
    Indian J Hematol Blood Transfus; 2023 Jan; 39(1):77-84. PubMed ID: 36091934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
    Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
    Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India.
    Gogia A; Nair S; Arora S; Kumar L; Sharma A; Gupta R; Biswas A; Mallick S
    Front Oncol; 2021; 11():770747. PubMed ID: 34926277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
    Witzig TE; Hong F; Micallef IN; Gascoyne RD; Dogan A; Wagner H; Kahl BS; Advani RH; Horning SJ
    Br J Haematol; 2015 Sep; 170(5):679-86. PubMed ID: 25974212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China.
    Zhou D; Li L; Bao C; Zhu J; Zhu L; Yang X; Zheng Y; Zhou M; Luo X; Xie W; Ye X
    Int J Clin Exp Med; 2015; 8(12):22497-502. PubMed ID: 26885233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma.
    Liu R; Chen Z; Wang S; Zhao G; Gu Y; Han Q; Chen B
    Mol Med Rep; 2019 Oct; 20(4):3679-3690. PubMed ID: 31485671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement.
    Kang BW; Moon JH; Chae YS; Lee SJ; Kim JG; Kim YK; Lee JJ; Yang DH; Kim HJ; Kim JY; Do YR; Park KU; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Ryoo HM; Bae SH; Kim H; Sohn SK
    Cancer Res Treat; 2013 Jun; 45(2):112-7. PubMed ID: 23864844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.
    Huang BT; Zeng QC; Yu J; Xiao Z; Li BS; Zhang CL; Ji HB
    J Cancer Res Clin Oncol; 2012 Jan; 138(1):125-32. PubMed ID: 22057732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.
    Hu C; Deng C; Zou W; Zhang G; Wang J
    Acta Haematol; 2015; 134(2):111-8. PubMed ID: 25925586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
    Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
    Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
    LaCasce AS; Vandergrift JL; Rodriguez MA; Abel GA; Crosby AL; Czuczman MS; Nademanee AP; Blayney DW; Gordon LI; Millenson M; Vanderplas A; Lepisto EM; Zelenetz AD; Niland J; Friedberg JW
    Blood; 2012 Mar; 119(9):2093-9. PubMed ID: 22234679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
    Odejide OO; Cronin AM; Davidoff AJ; LaCasce AS; Abel GA
    Leuk Lymphoma; 2015 Mar; 56(3):716-24. PubMed ID: 24913508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.
    Desai SH; Pederson L; LaPlant B; Mwangi R; Maurer M; Young JR; Macon WR; King RL; Wang Y; Cerhan JR; Feldman A; Inwards DJ; Micallef I; Johnston P; Porrata LF; Ansell SM; Habermann TM; Witzig TE; Nowakowski GS
    Blood Cancer J; 2022 May; 12(5):78. PubMed ID: 35504884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.
    Petronilho S; Sequeira JP; Paulino S; Lopes P; Lisboa S; Chacim S; Lobo J; Teixeira M; Jerónimo C; Henrique R
    J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.
    Conconi A; Zucca E; Margiotta-Casaluci G; Darling K; Hasse B; Battegay M; Staehelin C; Novak U; Schmid P; Scherrer A; Dirnhofer S; Kwee I; Nassi L; Cavalli F; Gaidano G; Bertoni F; Bernasconi E;
    Hematol Oncol; 2018 Dec; 36(5):757-764. PubMed ID: 30113708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis.
    He Y; Tao W; Ji D; Lu W; Xiong Y; Chen G
    Transl Cancer Res; 2021 May; 10(5):2044-2054. PubMed ID: 35116526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical outcome of 489 patients with diffuse large B-cell lymphoma and associated factors].
    Wen JJ; Zhou JL; Liu ZB; Xu CG
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):519-23. PubMed ID: 24941831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.
    Nolasco-Medina D; Reynoso-Noveron N; Mohar-Betancourt A; Aviles-Salas A; García-Perez O; Candelaria M
    Biomed Res Int; 2016; 2016():9817606. PubMed ID: 27478844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy.
    Xie W; Zhou D; Hu K; Xiao X; Huang W; He J; Shi J; Luo Y; Zhang J; Lin M; Cai Z; Huang H; Ye X
    Exp Ther Med; 2013 Jul; 6(1):109-114. PubMed ID: 23935730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.